Abstract:Abstract 2384 Introduction: Allogeneic haematopoietic stem cell transplantation (HSCT) has been used to treat malignant hematological diseases. For patients who do not have a matched sibling donor or a matched unrelated donor (MUD) for transplantation, an eligible HLA-haploidentical donor can be identified rapidly in nearly all cases. However, HLA-haploidentical BMT has been associated with significant risks of complication, such as graft rejection and severe GVHD and infection. Materials and Methods: Thirty eight consecutive patients with malignant hematological diseases received HLA-haploidentical stem cell transplant from April 2008 to June 2010. Eligible patients were 9– 48 years of age with acute myeloid leukemia (n=10),acute lymphocytic leukemia (n=17), myelodysplastic syndrome(n=5), chronic myeloid leukemia (n=4), non Hodgkin lymphoma (n=2). Transplantation conditioning consisted of Ara-C (4 g/m2/d, i.v.) on day -10 and -9, Bu (9.6mg/kg i.v. in 12 doses) on day -8, -7 and -6, Cy (1.8 g/m2/d, i.v.) on day -5 and -4, Me-CCNU (250 mg/kg, i.v.) on day -3, and ATG (2.5 mg/kg/d i.v.) on day -5 to -2. The prophylaxis of aGVHD consisted of cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate. Donors were primed with rhG-CSF (7.5 mg/kg per day) injected subcutaneous (s.c.). Bone marrow cells and peripheral blood stem cells(PBSC) were harvested in nineteen donors, and only PBSC were harvested in the other 19 donors. Results: Primary engraftment was achieved in all patients. All the patients achieved complete donor chimerism in the peripheral blood before day +28. Seven patients (18.4%) had grade I aGVHD, ten (26.3%) had grade II aGVHD, four(10.5%) had grade III aGVHD and four (10.5%) had grade IV aGVHD. II-IV aGVHD occurred in nine patients treated with bone marrow cells and PBSCs, the same number patients suffered from II-IV aGVHD treated with only PBSCs. Transplant related mortality within 100 days after transplantation was 15.8%. At a median follow-up of 10 months (range 2–28months), the overall survival was 68.4%. Conclusion: Haploidentical stem cell transplantation is relatively safe and efficient for the patients who have no HLA matched donors.The results require to confirm and show that G-BM combined with PBSC or G-PBSC from haploidentical family donors have equal effect. Disclosures: No relevant conflicts of interest to declare.

Clinical characteristics and outcomes of overt gastrointestinal bleeding in children undergoing haploidentical hematopoietic stem cell transplantation: a single-center retrospective analysis

Overt Gastrointestinal Bleeding Following Haploidentical Haematopoietic Stem Cell Transplantation: Incidence, Outcomes and Predictive Models

Clinical outcomes of unrelated cord blood transplantation in children with malignant and non-malignant diseases: Multicenter experience in China.

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

[Severe Gastrointestinal Bleeding after Allogeneic Hematopoietic Stem Cell Transplantation--15 Case Analysis].

Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998–2012

Clinical Analysis of Hemorrhagic Cystitis in Children and Adolescents with Hematological Diseases Post Haplo-Hematopoietic Stem Cell Transplantation

Prognostic Value and Prediction of Bleeding in Patients Undergoing Hematopoietic Stem-Cell Transplantation: A Retrospective Study of Chinese Group for Blood and Marrow Transplantation Working Party

Clinical Presentation and Outcome of Pediatric Patients with Hemophagocytic Lymphohistiocytosis in China: A Retrospective Multicenter Study

Features of gastrointestinal acute graft‐versus‐host disease in children undergoing hematopoietic stem cell transplantation

The Impact of Graft Composition on Clinical Outcomes in Pediatric Patients Undergoing Unmanipulated Hla-Mismatched/Haploidentical Hematopoietic Stem Cell Transplantation

Transplantation of Haploidentical Hematopoietic Stem Cells from Family Members Without in Vitro T-cell Depletion for Treatment of Hematologic Malignancies in Pediatric Patients

Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation.

[Analysis of Clinical Efficacy and Prognosis in 83 Cases Receiving Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies].

The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation

Intracranial Hemorrhage and Mortality in 1461 Patients after Allogeneic Hematopoietic Stem Cell Transplantation for 6-Year Follow-Up: Study of 44 Cases

Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation

Outcomes of blood and marrow transplantation in children less than 2-years of age: 23 years of experience at a single center

Clinical Characteristics and Risk Factors of Intracranial Hemorrhage in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation.

Prognoses and Complications of Patients with Hematological Malignancies after Haploidentical or Siblingidentical Donor Stem Cell Transplantations